Trial Profile

A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tideglusib (Primary) ; Tideglusib (Primary)
Indications Myotonic dystrophy
Focus Registrational; Therapeutic Use
Acronyms REACH CDM; REACH-CDM
Sponsors AMO Pharma

Most Recent Events

07 Sep 2023 Status changed from active, no longer recruiting to completed.
06 Sep 2023 Primary endpoint (Change in Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)) has not been met, according to an AMO Pharma media release.
06 Sep 2023 Results presented in an AMO Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com